Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
| العنوان: | Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study |
|---|---|
| المؤلفون: | Jerry Bagel, Carle Paul, Kurt Gebauer, Diamant Thaçi, Yin You, Susan Flavin, April W. Armstrong, Lyn Guenther, Andrew Blauvelt, Richard G. Langley, Kristian Reich, Bruce Randazzo, Ming-Chun Hsu |
| المصدر: | Journal of Dermatological Treatment. 33:2317-2324 |
| بيانات النشر: | Informa UK Limited, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Plaque psoriasis, Moderate to severe, medicine.medical_specialty, business.industry, Body Weight, Antibodies, Monoclonal, Dermatology, Antibodies, Monoclonal, Humanized, medicine.disease, Severity of Illness Index, Immunoglobulin A, Treatment Outcome, Guselkumab, Double-Blind Method, Psoriasis Area and Severity Index, Psoriasis, Internal medicine, medicine, Humans, Body region, Secukinumab, In patient, business, Aged |
| الوصف: | Purpose Guselkumab, an interleukin (IL)-23 inhibitor, effectively treats moderate-to-severe plaque psoriasis. Materials and methods ECLIPSE, was a Phase 3, multicenter, 56-week, double-blinded, active-comparator study of guselkumab vs. secukinumab (IL-17A inhibitor) in patients with moderate-to-severe psoriasis. Patients were treated with guselkumab 100 mg (n = 534) or secukinumab 300 mg (n = 514) through week 44. Efficacy (at least a 90% and 100% improvement from baseline in Psoriasis Area and Severity Index [PASI 90 and PASI 100], Investigator's Global Assessment [IGA] 0/1, and IGA 0) was analyzed across subpopulations defined by baseline: age ( Results Overall, 1048 patients were randomized. At week 48, numerically greater proportions of patients achieved PASI 90, PASI 100, IGA 0/1, and IGA 0 with guselkumab vs. secukinumab regardless of baseline age, body weight, BMI, disease severity, body region, and prior medication. The largest differences were in patients ≥65 years old and patients weighing >100 kg. Conclusions Guselkumab treatment provided greater efficacy vs. secukinumab at week 48 in most subpopulations of patients with psoriasis. |
| تدمد: | 1471-1753 0954-6634 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ef89250a34d6ef6ab5094331b342c1a https://doi.org/10.1080/09546634.2021.1959504 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....0ef89250a34d6ef6ab5094331b342c1a |
| قاعدة البيانات: | OpenAIRE |
PDF full text from Publisher | تدمد: | 14711753 09546634 |
|---|